A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects With Confirmed or Suspected Influenza Infection.

Trial Profile

A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects With Confirmed or Suspected Influenza Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Peramivir (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 11 Feb 2015 Duration of assessment of primary endpoint ''Change From Baseline in Influenza Virus Titer'' changed from Day 5 to 48 hours, also secondary endpoints added to the study as reported by ClinicalTrials.gov record.
    • 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 14 Jan 2011 Top line results have been reported in a BioCryst media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top